A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Metastatic Castrate Resistant Prostate Cancer Clinical Trial

Official title:
A Randomised, Double-Blind, Placebo-Controlled Proof Of Concept Study Of Maintenance Therapy With Tasquinimod In Patients With Metastatic Castrate-Resistant Prostate Cancer Who Are Not Progressing After A First Line Docetaxel Based Chemotherapy

Status Terminated

Clinical Trial Summary

The purpose of this study is to confirm that tasquinimod used as maintenance therapy is active and tolerable in patients with metastatic castrate-resistant prostate cancer not progressing after a first chemotherapy with docetaxel.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Metastatic Castrate Resistant Prostate Cancer
Prostatic Neoplasms

Clinical Trial Details

NCT number	NCT01732549
Study type	Interventional
Source	Ipsen
Contact
Status	Terminated
Phase	Phase 2
Start date	January 2013
Completion date	May 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03761225` - Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer	Phase 3
Recruiting	`NCT04038502` - Carboplatin or Olaparib for BRcA Deficient Prostate Cancer	Phase 2
Terminated	`NCT03729596` - MGC018 With or Without MGA012 in Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03737370` - Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer	Phase 1
Completed	`NCT01090765` - A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)	Phase 1/Phase 2
Suspended	`NCT03236688` - Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)